logo

For the Inventor, By the Inventor

Hochheim, Germany

Stefan Mullner

This inventor holds 23 USPTO granted patents, plus 1 CIPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Hoechst Aktiengesellschaft, Adventis Research & Technologies Gmbh & Co. Kg, Heochst Aktiengesellschaft. Active years: 1990-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefan Mullner. Retrieved from https://idiyas.com/inventor/stefan-mullner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23

% Patents Active = 100.0


Average Co-Inventor Count = 2.6

ph-index = 10

Forward Citations = 315(Granted Patents)


Location History:

  • Frankfurt-am-Main, DE (1990 - 1996)
  • Hochheim am Main, DE (1993 - 1998)
  • Hochheim, DE (1993 - 2000)
  • Hocheim am Main, DE (2000)

Company Filing History:

goldMedal20 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents
silverMedal1 out of 1 
 
Adventis Research & Technologies Gmbh & Co. Kg
 patent
bronzeMedal1 out of 3 
 
Heochst Aktiengesellschaft
 patents
4. 1 out of 834,570 
Other
 patents

Years Active: 1990-2000

Loading Chart...
Loading Chart...
Areas of Expertise:
Pharmaceuticals
Bile Acids
Xanthine Derivatives
Immunological Compounds
Isoxazole Derivatives
Polyaspartamide
Antibodies
Insulin Activity
Hydrophilic Polymers
Electrophoretic Separation
Lipoproteins
23 patents (USPTO):Explore Patents
1. 6140365 - Preparation of microorganisms comprising omega-3-fatty acid for use as a (2000-10-31),
2. 6121479 - Isoxazole and crotonamide derivatives and their use as pharmaceuticals (2000-09-19),
3. 6036948 - Polyaspartamide derivatives as adsordents for bile acids, (2000-03-14),
4. 6011051 - Use of isoxazole and crotonamide derivatives for the modulation of (2000-01-04),
5. 5990103 - Combination preparation for use in immunological diseases (1999-11-23),
6. 5981536 - Use of xanthine derivatives for the modulation of apoptosis (1999-11-09),
7. 5977151 - Isoxazole and crotonamide derivatives and their use as pharmaceuticals (1999-11-02),
8. 5976811 - Antibodies for the selective immunological determination of bile acids (1999-11-02),
9. 5856330 - Use of xanthine derivatives for the inhibition of dephosphorylation of (1999-01-05),
10. 5780592 - Compositions comprising lipoproteins and crotonamide derivatives (1998-07-14),
11. 5750679 - Process for obtaining pharmacologically active compounds from complex (1998-05-12),
12. 5728686 - Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their (1998-03-17),
13. 5714138 - Polyaspartamide derivatives as adsorbents for bile acids, (1998-02-03),
14. 5624903 - Phosphoinositol-glycan-peptide with insulin-like action (1997-04-29),
15. 5514599 - Antibodies against highly conserved amino acid sequences of insulin a (1996-05-07),

Title: Stefan Mullner - Innovative Inventor from Hochheim

Introduction: Stefan Mullner is a renowned inventor hailing from Hochheim, Germany, known for his groundbreaking contributions to various industries.

Latest Patents: Stefan Mullner holds several patents in the fields of renewable energy, sustainable technology, and advanced materials, showcasing his commitment to innovation.

Career Highlights: With a career spanning over two decades, Stefan Mullner has worked with leading research institutions and companies to develop cutting-edge solutions that have revolutionized the way we approach challenges in the modern world.

Collaborations: Throughout his career, Stefan Mullner has collaborated with top engineers, scientists, and designers, fostering a culture of creativity and excellence that has led to numerous successful projects and inventions.

Conclusion: Stefan Mullner's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…